Periventricular hyperintensities are associated with elevated cerebral amyloid

Neurology

Volumn 86, Issue 6, 2016, Pages 535-543

  Marnane, Michael ^a,b   Al Jawadi, Osama O ^a   Mortazavi, Shervin ^a   Pogorzelec, Kathleen J ^a   Wang, Bing Wei ^a   Feldman, Howard H ^a,b   Hsiung, Ging Yuek R ^a,b  

^a Djavad Mowafaghian Center for Brain Health   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CHOLINESTERASE INHIBITOR; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE; MEMANTINE; TAU PROTEIN; BIOLOGICAL MARKER;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EDUCATION; ETHNICITY; FEMALE; FRONTAL CORTEX; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PARIETAL CORTEX; PERIVENTRICULAR WHITE MATTER HYPERINTENSITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE PRESSURE; RACE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; SEX; WHITE MATTER LESION; ADULT; BRAIN VENTRICLE; CEREBROSPINAL FLUID; COGNITIVE DYSFUNCTION; MIDDLE AGED; PATHOLOGY; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BIOMARKERS; CEREBRAL VENTRICLES; COGNITIVE DYSFUNCTION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES;

EID: 84957798708     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002352     Document Type: Article

References (36)

1. Thal DR, Attems J, Ewers M. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies. J Alzheimers Dis 2014;42:S421-S429.
2. Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement 2015;11: 710-717.
3. Weller RO, Hawkes CA, Kalaria RN, Werring DJ, Carare RO. White matter changes in dementia: role of Impaired drainage of interstitial fluid. Brain Pathol 2014;25:63-78.
4. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment: a critical update. Front Aging Neurosci 2013;5:17.
5. Moody DM, Bell MA, Challa VR. Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. AJNR Am J Neuroradiol 1990;11:431-439.
6. Gouw AA, Seewann A, van der Flier WM, et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126-135.
7. Conklin J, Silver FL, Mikulis DJ, Mandell DM. Are acute infarcts the cause of leukoaraiosis? Brain mapping for 16 consecutive weeks. Ann Neurol 2014;76:899-904.
8. Duering M, Csanadi E, Gesierich B, et al. Incident lacunes preferentially localize to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. Brain 2013;136:2717-2726.
9. Jack CR Jr, Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement 2010; 6:212-220.
10. DeCarli C, Fletcher E, Ramey V, Harvey D, Jagust WJ. Anatomical mapping of white matter hyperintensities (WMH): exploring the relationships between periventricular WMH, deep WMH, and total WMH burden. Stroke 2005;36:50-55.
11. Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of beta-amyloid. Ann Neurol 2013;74: 826-836.
12. Alzheimer Disease Neuroimaging Initiative investigators. ADNI-go PET Technical Procedures Manual AV-45 & FDG. Available at: http://www.adni-info.org/Scientists/doc/ADNIGO-PET-Tech-Manual-01142011.pdf. Accessed May 14, 2015.
13. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011;32: 1207-1218.
14. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65: 403-413.
15. Hallgren KA. Computing Inter-rater reliability for observational data: an overview and tutorial. Tutor Quant Methods Psychol 2012;8:23-34.
16. Chiang GC, Cruz Hernandez JC, Kantarci K, Jack CR Jr, Weiner MW; Alzheimer's Disease Neuroimaging Initiative. Cerebral microbleeds, CSF p-tau, and cognitive decline: significance of anatomic distribution. AJNR Am J Neuroradiol 2015;36:1635-1641.
17. Yamada S, Saiki M, Satow T, et al. Periventricular and deep white matter leukoaraiosis have a closer association with cerebral microbleeds than age. Eur J Neurol 2012;19: 98-104.
18. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol 2008;18:253-266.
19. Iliff JJ, Wang M, Zeppenfeld DM, et al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J Neurosci 2013;33: 18190-18199.
20. Vinters HV, Gilbert JJ. Cerebral amyloid angiopathy: incidence and complications in the aging brain: II: the distribution of amyloid vascular changes. Stroke 1983; 14:924-928.
21. Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol 2011;70:871-880.
22. Thanprasertsuk S, Martinez-Ramirez S, Pontes-Neto OM, et al. Posterior white matter disease distribution as a predictor of amyloid angiopathy. Neurology 2014;83:794-800.
23. Park JH, Seo SW, Kim C, et al. Pathogenesis of cerebral microbleeds: in vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Ann Neurol 2013;73:584-593.
24. Holland CM, Smith EE, Csapo I, et al. Spatial distribution of white-matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke 2008;39:1127-1133.
25. Ewers M, Brendel M, Rizk-Jackson A, et al. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. Neuroimage Clin 2014;4:45-52.
26. Brickman AM, Provenzano FA, Muraskin J, et al. Regional white matter hyperintensity volume, not hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol 2012;69:1621-1627.
27. Polvikoski TM, van Straaten EC, Barkhof F, et al. Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 2010;75:2071-2078.
28. Whitwell JL, Lowe VJ, Duffy JR, et al. Elevated occipital beta-amyloid deposition is associated with widespread cognitive impairment in logopenic progressive aphasia. J Neurol Neurosurg Psychiatry 2013;84:1357-1364.
29. Rutten-Jacobs LC, de Leeuw FE, Geurts-van Bon L, et al. White matter lesions are not related to beta-amyloid deposition in an autopsy-based study. Curr Gerontol Geriatr Res 2011;2011:826862.
30. Stenset V, Hofoss D, Johnsen L, et al. White matter lesion load increases the risk of low CSF Ab42 in apolipoprotein E-e4 carriers attending a memory clinic. J Neuroimaging 2011;21:e78-82.
31. Kester MI, Goos JD, Teunissen CE, et al. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. JAMA Neurol 2014;71:855-862.
32. Haight TJ, Landau SM, Carmichael O, et al. Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol 2013; 70:1039-1045.
33. Benedictus MR, Goos JD, Binnewijzend MA, et al. Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. Neurobiol Aging 2013; 34:2488-2494.
34. Guzman VA, Carmichael OT, Schwarz C, et al. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. Alzheimers Dement 2013;9:S124-S131.
35. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-269.
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.